When IBD patients self-report their adverse reactions to biological therapies, they could provide insights that shape and optimize treatments.
That’s the goal of a recently created pharmacovigilance system to survey how patients think about and reacted to drug therapies. Understanding the patient experience could ultimately help bolster treatments, according to Pepjin Thomas, a doctoral candidate in the Department of Gastroenterology at Radboud University Medical Center, in Nijmegen, the Netherlands. “I think it will mainly add finding out what patients consider as adverse drug reactions and if that’s clear, you can improve medication adherence.”